Vanguard Capital Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$315M Buy
5,401,661
+575,044
+12% +$33.9M 0.01% 856
2026
Q2
$271M Buy
4,826,617
+294,731
+7% +$15.3M 0.01% 965
2026
Q1
$217M Buy
+4,531,886
New +$198M 0.01% 1018

Other funds holding RPRX

Vanguard Capital Management's RPRX Position: Q3 2026 in Review

Vanguard Capital Management increased its Royalty Pharma (RPRX) stake by 12% in Q3 2026, buying an estimated $33.9M and bringing the position to 5,401,661 shares worth $315M. The position accounts for 0.01% of the portfolio, ranked #856.

Vanguard Capital Management first reported a position in RPRX in Q1 2026 and has held it in 3 quarters since. 703 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Vanguard Capital Management held 5,401,661 shares of Royalty Pharma worth $315M as of Q3 2026.
  • Vanguard Capital Management bought 575,044 Royalty Pharma shares in Q3 2026, an estimated $33.9M.
  • Royalty Pharma made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #856 holding.
  • Vanguard Capital Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 3 quarters since.
  • 703 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.